.png)
.png)
Stevenage Bioscience Catalyst strengthens Board with appointment of two new Non-Executive Directors
Today, Stevenage Bioscience Catalyst (SBC) has announced the appointment of two new Non-Executive Directors (NEDs) to its Board. Clare Terlouw, Head of Corporate Development at Syncona Investment Management Limited and Jon Green, Chair of One Nucleus, will be joining the SBC Board on 1st October 2019.
Clare is Head of Corporate Development at Syncona Investment Management Limited and has 15 years’ experience as a specialist healthcare and life sciences corporate financier in London. She joined Syncona from Numis Securities, where she was a Managing Director, Healthcare & Life Sciences, Corporate Advisory and Broking. Her focus was on advising LSE Main Market and AIM listed healthcare and life sciences companies and she has extensive experience across a range of financing and M&A transactions for growing, innovative healthcare companies. Clare was previously at Nomura Code and Peel Hunt, and was an orthopaedic physiotherapist treating patients for acute sport and trauma injuries. Clare is also a Board member of the UK Bioindustry Association.
Jon is Chair of the Board of One Nucleus, Vice Chair of the Pharmaceutical Industry Security Forum and Chair of the Advisory Board for Horus, a security consultancy. After starting his career in scientific roles at Imperial College and the Medical Research Council, Jon held multiple leadership positions at Cambridge Antibody Technology and MedImmune, most recently as VP of R&D, Cambridge site operations. Jon has an MPhil in Cellular Pathology, is a Chartered Biologist, a Fellow of the Royal Society of Biology, Fellow of the Royal Society of Arts and Manufacturing, and Fellow of the Institute of Directors.
Dr Sally Ann Forsyth, Chief Executive Officer at Stevenage Bioscience Catalyst, commented “I would like to extend a very warm welcome to Clare and Jon as they join our Board. Their extensive expertise across the life science sector will further strengthen our ability to build a globally recognised cluster for therapeutics that provides outstanding support for the translation and commercialisation of innovative new medicines.”
Clare Terlouw, Head of Corporate at Syncona Investment Management Limited, said “I am delighted to join the Board of Stevenage Bioscience Catalyst. Over the last 7 years, Stevenage has become a hub of life sciences innovation in the UK. The Catalyst is home to an exciting set of emerging companies and provides crucial infrastructure to them as they grow and innovate. I am looking forward to working with my fellow Board members to support the Catalyst’s continued development.”
Jon Green, Chair of One Nucleus, commented “I feel very privileged to be appointed to the Board of Stevenage Bioscience Catalyst at this exciting stage of its development. The Catalyst has gone from strength to strength in the last few years and I am looking forward to contributing to the Board, and ensuring that the Catalyst fulfils its great ambitions and more, in the years to come.”
Clare is Head of Corporate Development at Syncona Investment Management Limited and has 15 years’ experience as a specialist healthcare and life sciences corporate financier in London. She joined Syncona from Numis Securities, where she was a Managing Director, Healthcare & Life Sciences, Corporate Advisory and Broking. Her focus was on advising LSE Main Market and AIM listed healthcare and life sciences companies and she has extensive experience across a range of financing and M&A transactions for growing, innovative healthcare companies. Clare was previously at Nomura Code and Peel Hunt, and was an orthopaedic physiotherapist treating patients for acute sport and trauma injuries. Clare is also a Board member of the UK Bioindustry Association.
Jon is Chair of the Board of One Nucleus, Vice Chair of the Pharmaceutical Industry Security Forum and Chair of the Advisory Board for Horus, a security consultancy. After starting his career in scientific roles at Imperial College and the Medical Research Council, Jon held multiple leadership positions at Cambridge Antibody Technology and MedImmune, most recently as VP of R&D, Cambridge site operations. Jon has an MPhil in Cellular Pathology, is a Chartered Biologist, a Fellow of the Royal Society of Biology, Fellow of the Royal Society of Arts and Manufacturing, and Fellow of the Institute of Directors.
Dr Sally Ann Forsyth, Chief Executive Officer at Stevenage Bioscience Catalyst, commented “I would like to extend a very warm welcome to Clare and Jon as they join our Board. Their extensive expertise across the life science sector will further strengthen our ability to build a globally recognised cluster for therapeutics that provides outstanding support for the translation and commercialisation of innovative new medicines.”
Clare Terlouw, Head of Corporate at Syncona Investment Management Limited, said “I am delighted to join the Board of Stevenage Bioscience Catalyst. Over the last 7 years, Stevenage has become a hub of life sciences innovation in the UK. The Catalyst is home to an exciting set of emerging companies and provides crucial infrastructure to them as they grow and innovate. I am looking forward to working with my fellow Board members to support the Catalyst’s continued development.”
Jon Green, Chair of One Nucleus, commented “I feel very privileged to be appointed to the Board of Stevenage Bioscience Catalyst at this exciting stage of its development. The Catalyst has gone from strength to strength in the last few years and I am looking forward to contributing to the Board, and ensuring that the Catalyst fulfils its great ambitions and more, in the years to come.”